Loading clinical trials...

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.

NCT00281632•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.

Eligibility

Age

21 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
•Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin).
•Has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol.
•Is on a specifically prohibited medication or requires these medications during treatment with GW786034.

Exclusion Criteria

•Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy.
•Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or higher).
•Currently taking warfarin.
•Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.

Locations (10)

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Bedford, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Fort Worth, Texas, United States

GSK Investigational Site

Randwick, New South Wales, Australia

GSK Investigational Site

Herston, Queensland, Australia

GSK Investigational Site

Melbourne, Australia

GSK Investigational Site

Singapore, Singapore

GSK Investigational Site

Singapore, Singapore

Key Dates

Start Date

March 1, 2006

Primary Completion Date

April 1, 2008

Completion Date

October 1, 2010

Last Updated

September 17, 2018

Enrollment

ACTUAL participants

Conditions

Peritoneal CancerOvarian CancerNeoplasms, OvarianFallopian Tube Cancer

Interventions

GW786034

DRUG

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 17, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)